Kevin Kalinsky1, Katherine D Crew, Susan Refice, Tong Xiao, Antai Wang, Sheldon M Feldman, Bret Taback, Aqeel Ahmad, Serge Cremers, Hanina Hibshoosh, Matthew Maurer, Dawn L Hershman. 1. Department of Medicine, College of Physicians and Surgeons,1 Herbert Irving Comprehensive Cancer Center,2 Departments of Epidemiology and Biostatistics, Mailman School of Public Health,3 Department of Surgery, College of Physicians and Surgeons,4 Department of Medicine, Laboratory Irving Institute for Clinical and Translational Research, College of Physicians and Surgeons,5 Department of Pathology and Cell Biology,6 College of Physicians and Surgeons, Columbia University, New York, New York, USA.
Abstract
INTRODUCTION: We conducted a presurgical trial to assess the tissue-related effects of metformin in overweight/obese breast cancer (BC) patients. METHODS: Metformin 1,500 mg daily was administered to 35 nondiabetics with stage 0-III BC, body mass index (BMI) ≥ 25 kg/m(2). The primary endpoint was tumor proliferation change (i.e., ki-67). Tumor proliferation change was compared to untreated historical controls, matched by age, BMI, and stage. RESULTS: There was no reduction in ln(ki-67) after metformin (p = .98) or compared to controls (p = .47). There was a significant reduction in BMI, cholesterol, and leptin. CONCLUSION: Despite no proliferation changes, we observed reductions in other relevant biomarkers.
INTRODUCTION: We conducted a presurgical trial to assess the tissue-related effects of metformin in overweight/obese breast cancer (BC) patients. METHODS:Metformin 1,500 mg daily was administered to 35 nondiabetics with stage 0-III BC, body mass index (BMI) ≥ 25 kg/m(2). The primary endpoint was tumor proliferation change (i.e., ki-67). Tumor proliferation change was compared to untreated historical controls, matched by age, BMI, and stage. RESULTS: There was no reduction in ln(ki-67) after metformin (p = .98) or compared to controls (p = .47). There was a significant reduction in BMI, cholesterol, and leptin. CONCLUSION: Despite no proliferation changes, we observed reductions in other relevant biomarkers.
Authors: Rebecca E Hasson; Tanja C Adam; Jaimie N Davis; Marc J Weigensberg; Emily E Ventura; Christianne J Lane; Christian K Roberts; Michael I Goran Journal: J Clin Endocrinol Metab Date: 2010-05-05 Impact factor: 5.958
Authors: Sirwan Hadad; Takayuki Iwamoto; Lee Jordan; Colin Purdie; Susan Bray; Lee Baker; Gera Jellema; Steve Deharo; D Grahame Hardie; Lajos Pusztai; Stacy Moulder-Thompson; John A Dewar; Alastair M Thompson Journal: Breast Cancer Res Treat Date: 2011-06-08 Impact factor: 4.872
Authors: Saroj Niraula; Ryan J O Dowling; Marguerite Ennis; Martin C Chang; Susan J Done; Nicky Hood; Jaime Escallon; Wey Liang Leong; David R McCready; Michael Reedijk; Vuk Stambolic; Pamela J Goodwin Journal: Breast Cancer Res Treat Date: 2012-08-30 Impact factor: 4.872
Authors: Phil Zeitler; Kathryn Hirst; Laura Pyle; Barbara Linder; Kenneth Copeland; Silva Arslanian; Leona Cuttler; David M Nathan; Sherida Tollefsen; Denise Wilfley; Francine Kaufman Journal: N Engl J Med Date: 2012-04-29 Impact factor: 91.245
Authors: A DeCensi; A Guerrieri-Gonzaga; S Gandini; D Serrano; M Cazzaniga; S Mora; H Johansson; E A Lien; G Pruneri; G Viale; B Bonanni Journal: Ann Oncol Date: 2010-08-17 Impact factor: 32.976
Authors: Mitch Dowsett; Torsten O Nielsen; Roger A'Hern; John Bartlett; R Charles Coombes; Jack Cuzick; Matthew Ellis; N Lynn Henry; Judith C Hugh; Tracy Lively; Lisa McShane; Soon Paik; Frederique Penault-Llorca; Ljudmila Prudkin; Meredith Regan; Janine Salter; Christos Sotiriou; Ian E Smith; Giuseppe Viale; Jo Anne Zujewski; Daniel F Hayes Journal: J Natl Cancer Inst Date: 2011-09-29 Impact factor: 13.506
Authors: M Elizabeth H Hammond; Daniel F Hayes; Mitch Dowsett; D Craig Allred; Karen L Hagerty; Sunil Badve; Patrick L Fitzgibbons; Glenn Francis; Neil S Goldstein; Malcolm Hayes; David G Hicks; Susan Lester; Richard Love; Pamela B Mangu; Lisa McShane; Keith Miller; C Kent Osborne; Soonmyung Paik; Jane Perlmutter; Anthony Rhodes; Hironobu Sasano; Jared N Schwartz; Fred C G Sweep; Sheila Taube; Emina Emilia Torlakovic; Paul Valenstein; Giuseppe Viale; Daniel Visscher; Thomas Wheeler; R Bruce Williams; James L Wittliff; Antonio C Wolff Journal: J Clin Oncol Date: 2010-04-19 Impact factor: 44.544
Authors: Brandy M Heckman-Stoddard; Andrea DeCensi; Vikrant V Sahasrabuddhe; Leslie G Ford Journal: Diabetologia Date: 2017-08-03 Impact factor: 10.122
Authors: K Kalinsky; J A Sparano; X Zhong; E Andreopoulou; B Taback; L Wiechmann; S M Feldman; P Ananthakrishnan; A Ahmad; S Cremers; A N Sireci; J R Cross; D K Marks; P Mundi; E Connolly; K D Crew; M A Maurer; H Hibshoosh; S Lee; D L Hershman Journal: Clin Transl Oncol Date: 2018-05-07 Impact factor: 3.405
Authors: Ronald A Lubet; Brandy M Heckman-Stoddard; Jennifer T Fox; Fariba Moeinpour; M Margaret Juliana; Robert H Shoemaker; Clinton J Grubbs Journal: Cancer Prev Res (Phila) Date: 2019-12-23
Authors: Elizabeth M Cespedes Feliciano; Candyce H Kroenke; Jeffrey A Meyerhardt; Carla M Prado; Patrick T Bradshaw; Andrew J Dannenberg; Marilyn L Kwan; Jingjie Xiao; Charles Quesenberry; Erin K Weltzien; Adrienne L Castillo; Bette J Caan Journal: J Clin Oncol Date: 2016-10-20 Impact factor: 44.544
Authors: K Kalinsky; T Zheng; H Hibshoosh; X Du; P Mundi; J Yang; S Refice; S M Feldman; B Taback; E Connolly; K D Crew; M A Maurer; D L Hershman Journal: Clin Transl Oncol Date: 2016-06-15 Impact factor: 3.405
Authors: Brandy M Heckman-Stoddard; Sara Gandini; Matteo Puntoni; Barbara K Dunn; Andrea DeCensi; Eva Szabo Journal: Semin Oncol Date: 2015-09-08 Impact factor: 4.929
Authors: Jessica K Paulus; Christina D Williams; Furha I Cossor; Michael J Kelley; Robert E Martell Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-08-05 Impact factor: 4.254